Clinical outcomes for MM are dependent on the tumor cell characteristics (measured by cytogenetics and fluorescence via in situ hybridization, FISH) and a laboratory evaluation of the tumor burden (measured by β2 microglobulin, LDH, and albumin) and is referred to as the revised international staging system (R-ISS). Here, HLA-G is linked to neoplasm.